POTELIGEO Efficacy and Safety

Hear Andrei Shustov, MD discuss the value of key endpoints used in the phase 3 MAVORIC trial, patient types appropriate for treatment with POTELIGEO, and the most common adverse reactions reported in MAVORIC.

Diagnosis

Elise Olsen, MD, PhD, Professor of Dermatology and Medicine, Duke University Health System and Founder and Director, Duke Cutaneous Lymphoma Research and Treatment Center, discusses best practices for diagnosis of Mycosis Fungoides and Sézary Syndrome, including how to differentiate them from other skin conditions and how to work collaboratively with a multidisciplinary team.

Patient Identification

Andrei Shustov, MD discusses identifying therapy-refractive patients, how blood involvement can impact treatment selection, how clinical practice guidelines help shape decisions, and appropriate patient types for treatment with POTELIGEO based on data from the phase 3 MAVORIC trial.

Patient Communication

Lauren C. Pinter-Brown, MD, clinical professor of Hematology/Oncology at the University of California, Irvine, discusses how to communicate with patients who have Mycosis Fungoides or Sézary Syndrome on topics including disease state, prognosis, blood involvement, staging, and prescribing.

Patient Monitoring & Adherence

Christiane Querfeld, MD, PhD, Director of the Cutaneous Lymphoma Program and Professor of Dermatology/ Dermatopathology at City of Hope, provides her expert point of view on how to monitor the progress of Mycosis Fungoides or Sézary Syndrome patients, managing treatment expectations, and ensuring adherence to treatment.

Disease Progression & Patient Management

Watch Francine Foss, MD, Professor of Medicine (Hematology and Dermatology) at Smilow Cancer Hospital at Yale New Haven discuss her approach to evaluating disease progression and managing patients with Mycosis Fungoides or Sézary Syndrome for response to treatment. She explains how the disease involves multiple compartments, such as skin and blood, which require unique assessments, examinations, and tools for monitoring Mycosis Fungoides or Sézary Syndrome progression.

Treatment Considerations

Watch Francine Foss, MD, Professor of Medicine (Hematology and Dermatology) at Smilow Cancer Hospital at Yale New Haven discuss treatment considerations for patients with Mycosis Fungoides or Sézary Syndrome. Dr Foss addresses different treatment options based on staging, clinical practice guidelines, blood involvement, and patient feedback.

The MAVORIC Trial Patient Population

Explore the diverse patient population and key efficacy results of POTELIGEO vs vorinostat.¹

POTELIGEO Efficacy in Skin

Learn about the response of POTELIGEO in skin, based on a post hoc analysis of data in the MAVORIC clinical trial.¹

POTELIGEO Efficacy in Blood

Look at the response of POTELIGEO in the blood, based on a post hoc analysis of data in the MAVORIC clinical trial.¹

How POTELIGEO Uniquely Targets CCR4

Learn about the role of C-C chemokine receptor type 4 (CCR4) in Mycosis Fungoides and Sézary Syndrome, and how POTELIGEO kills CCR4+ malignant T cells.¹

Long-term Safety Follow-up

See the results of post-MAVORIC trial analysis of safety in patients with POTELIGEO treatment exposure up to 5 years.